AbCheck
AbCheck s.r.o. is a Czech biotech that provides a proprietary microfluidics-based antibody discovery platform for discovering and optimizing human therapeutic antibodies, serving both research and commercial customers across multiple animal models.
- Company typePrivate
- Founded2019
- HeadquartersPlzen, Czechia
- Headcount11–50
- GTM typeB2B
- OfferingServices
What AbCheck does
AbCheck s.r.o. is a privately held Czech biotech company headquartered in Plzen, Czech Republic, operating in the antibody discovery and therapeutic optimization space. The company provides an antibody discovery platform that discovers and optimizes human therapeutic antibodies, with its core technical differentiator being a proprietary microfluidics-based platform used to perform functional assays.
The microfluidics technology originated from a 2019 grant awarded by the Czech Republic's Ministry of Industry and Trade and was developed beyond the originally scoped R&D objectives. By March 2023, AbCheck had successfully completed its R&D activities, expanding the platform to encompass functional assays applicable across multiple animal models. The platform has since been deployed in both research and commercial projects, with the company indicating that additional partnerships are in development around the technology.
AbCheck's customer orientation is horizontal, addressing both research and commercial use cases without a disclosed primary end-market segment. The company is structured as a Czech private limited company (s.r.o.), has 11-50 employees, and its only disclosed external capital consists of the 2019 government grant and a subsequent funding event of approximately $1.06 million dated 2023-03-09. Pricing is not publicly disclosed, no named customers or revenue figures are available, and the company does not maintain disclosed app, API, or integration products. Geographic operations are referenced primarily within the Czech Republic, with no claim of a global footprint.
AbCheck firmographics
Firmographics- Name
- AbCheck
- Legal name
- AbCheck s.r.o.
- Website
- https://abcheckantibodies.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AbCheck s.r.o. is a Czech biotech that provides a proprietary microfluidics-based antibody discovery platform for discovering and optimizing human therapeutic antibodies, serving both research and commercial customers across multiple animal models.
- Ownership category
- akta.pro rank
AbCheck industry classification
Industry- Product category
- Antibody Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK), High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)
Keywords
Where AbCheck is headquartered
LocationHeadquarters
- HQ city
- Plzen
- HQ country
- Czechia
- HQ region
- Europe
Markets served
AbCheck business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
AbCheck product offering
Product offeringCore offering
AbCheck provides an antibody discovery platform that discovers and optimizes human therapeutic antibodies, using proprietary microfluidics-based functional assay technology. The platform supports both research and commercial projects and is applicable across multiple animal models for drug discovery and development applications.
Differentiator
Problem solved
Functional benefit
Products and services
- Antibody Discovery Platform Proprietary microfluidics-based antibody discovery and optimization service for human therapeutic antibodies, applicable across multiple animal models for research and commercial projects.
- Microfluidics Functional Assays Functional assays powered by proprietary microfluidics technology for use in drug discovery and development research across multiple animal models.
Companies that use AbCheck
Customer profileSegments1 record
Ideal customer profiles1 record
AbCheck technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
AbCheck partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Ministry of Industry and Trade (Czech Republic)coreThe Czech Republic's Ministry of Industry and Trade awarded AbCheck a grant in 2019 to develop microfluidics technology. The R&D was successfully completed, with the technology developed beyond the original scope. Additional partnerships are currently in development for this technology platform.
Recent moves4 records
Expansion highlights3 records
AbCheck competitors and assessment
Company assessmentDirect peers
- AbCellera Biologics: Public antibody discovery platform combining single-cell screening, microfluidics, and AI to discover and optimize therapeutic antibodies for pharma partners. Directly comparable business model and core technology overlap with AbCheck's microfluidics-based antibody discovery focus.
- Adimab: Private yeast display-based antibody discovery and optimization platform serving large pharma with partnership-based economics. Directly comparable as a specialized antibody discovery service provider targeting the same therapeutic antibody customers as AbCheck.
- Ablexis: Antibody discovery platform leveraging transgenic mice and human antibody libraries, offering licensing and partnered discovery programs. Comparable as a focused antibody discovery platform serving therapeutic antibody developers.
- Specifica (a Q² Solutions company): Antibody discovery company using proprietary antibody libraries and high-throughput screening to deliver therapeutic antibody candidates. Directly comparable as an antibody discovery service provider with similar workflow focus.
- Distributed Bio (now AbStudio): Antibody discovery and engineering platform offering library design, immune repertoire sequencing, and optimization services. Comparable to AbCheck as a specialized discovery/optimization services provider for therapeutic antibodies.
Broad incumbents
- GenScript Biotech: Global life sciences services and CDMO company with a substantial antibody discovery, synthesis, and production portfolio. Comparable as a much larger incumbent offering antibody services overlapping AbCheck's customer base.
- WuXi Biologics: Global CRDMO providing end-to-end biologics discovery, development, and manufacturing including antibody discovery services. Broad incumbent in AbCheck's customer market with significantly greater scale.
- Lonza Group: Global CDMO offering integrated biologics services including antibody discovery, cell line development, and manufacturing. A large incumbent that competes for the same therapeutic antibody customer wallet.
- Charles River Laboratories: Major CRO providing discovery and safety assessment services, including antibody and biologics-related capabilities. Comparable as a broad life sciences services provider serving pharma with discovery and preclinical offerings.
Regional players
- Eurofins Discovery: European-headquartered CRO offering a broad portfolio of discovery and preclinical services, including assay development and antibody-related offerings. Comparable regional player with strong European footprint competing in AbCheck's home geography.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks6 records
Key highlights4 records
Customer concentration
AbCheck financial estimates
Financial estimateRevenue estimate
Valuation estimate
AbCheck leadership team
Management profileNumber of profiles
AbCheck funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AbCheck M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AbCheck
What does AbCheck do?
AbCheck provides an antibody discovery platform that discovers and optimizes human therapeutic antibodies, using proprietary microfluidics-based functional assay technology. The platform supports both research and commercial projects and is applicable across multiple animal models for drug discovery and development applications.
Is AbCheck a public or private company?
AbCheck is a private company. It is classified as unknown and is currently operating.
When was AbCheck founded?
AbCheck was founded in 2019. It employs 11 to 50 people.
Where is AbCheck based?
AbCheck is headquartered in Plzen, Czechia, in the Europe region.
Who are AbCheck's main competitors?
Direct peers on record are AbCellera Biologics, Adimab, Ablexis, Specifica (a Q² Solutions company) and Distributed Bio (now AbStudio). Broad incumbents are GenScript Biotech, WuXi Biologics, Lonza Group and Charles River Laboratories. Eurofins Discovery is listed as a regional player.
Does AbCheck have an API?
No public API is recorded for AbCheck.
What industry is AbCheck in?
AbCheck's product category is Antibody Discovery Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAK, In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy). Its NAICS code is 541714 and its SIC code is 2836.